Novozymes Biopharma has entered a collaborative research agreement with an undisclosed vaccine company to evaluate its modified recombinant human albumin (rAlbumin) Veltis technology to assess the dosing and performance of a subunit antigen vaccine candidate.   Subunit vaccines are regarded as a safer and more specific alternative to live attenuated vaccines, but are often limited by multiple dosing requirements and the need for adjuvants to improve the immune response. Novozymes’ VELTIS t...